You are here
ANG1005 - A Promising New Targeted Taxane Derivative
ANG1005 is a novel targeted taxane derivative, and represents the first oncology product to leverage the LRP-1 pathway to cross the blood-brain barrier (BBB) and enter cancer cells.
ANG1005 has solid Phase 1 clinical data demonstrating it to be highly active as a single agent, and is a Phase 2 ready CNS-active taxane for brain cancers.
ANG1005 Mechanism of Action
- ANG1005 gains entry into the brain by targeting the low-density lipoprotein receptor-related protein (LRP-1) which is one of the most highly expressed receptors on the surface of the BBB.
- Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain.
ANG1005 Clinical Data
ANG1005 has been evaluated in two separate Phase 1 multi-center, open-label, dose escalation clinical trials to identify the maximum tolerated dose (MTD) and obtain data on safety, tolerability and preliminary evidence of efficacy in patients with heavily pre-treated advanced solid tumors with brain metastases and in patients with recurrent malignant glioma.
Studying ANG1005 in Progressive Brain Metastases
Topline Results: ANG1005 demonstrated preliminary evidence of single agent activity against brain metastases arising from a variety of epithelial malignancies, including non-small cell lung cancer (NSCLC), breast cancer and ovarian cancer.
In the Phase 1 clinical trial, the response rate of patients who received therapeutic doses of ANG1005 was 24% (5/21). At the MTD, the response rate was 42% (5/12).
Furthermore, 33% (4/12) of patients previously treated with a taxane responded to treatment with ANG1005, indicating that ANG1005 has the potential to be effective against paclitaxel resistant tumors.
In addition to metastases in the brain, responses were also observed in bone, liver, and lymph metastases.
Studying ANG1005 in Recurrent Glioma
Topline Results: In the Phase 1 clinical trial in patients with recurrent glioma, 14% (4/28) of patients responded to treatment with ANG1005 with two patients achieving a complete response.
Therapeutic doses of ANG1005 were present in brain tumor samples taken from patients who had received a single dose of the drug, indicating that the drug successfully crossed the BBB and was concentrated in the tumor, without showing CNS toxicity or immunogenicity.
Plasma concentrations of ANG1005, both peak concentration (Cmax) and Area Under the Curve (AUC) were several fold higher at the MTD than has been previously demonstrated with naked paclitaxel.
Toxicities related to ANG1005 were similar to other taxanes, such as paclitaxel, with dose-limiting toxicity due to neutropenia.
Data Presented at ASCO 2010
Data from the Phase 1 clinical trials of ANG1005 were presented at the 2010 American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
> Download the posters and presentations
Further Development Plans
A Phase 2 clinical program has been developed to confirm the clinical activity of ANG1005 observed in earlier studies and identify relevant patient populations.